GHENT, BELGIUM – April 24, 2025 Ghent-based medtech startup Nuclivision has raised €5 million from renowned investors, including LUMO Labs, Heran Partners, and the imec.istart future fund, for the commercial rollout of their AI software platform Nuclarity that enables faster, safer, and more affordable medical imaging through PET scans.
PET (positron emission tomography) is a powerful imaging technique that makes it possible to visualize physiological processes, such as the energy consumption of cells, and abnormalities thereof. However, the radiotracers used come with costs and radiation risks, which currently limits accessibility.
Nuclivision’s software makes it possible to perform scans with less radiation and in a shorter time, without compromising on image quality. This represents a breakthrough for the use of medical imaging in the early detection and treatment of cancer and Alzheimer’s.
“Medical imaging is at an inflection point,” says Nuclivision’s CEO, Maarten Larmuseau. “With the rapid growth within radiopharma and theranostics, the use of AI and smart software is becoming necessary to handle the increased demand for PET and SPECT scans for conditions such as cancer and Alzheimer’s.”
With its groundbreaking software, Nuclivision aims to not only improve the quality of care but also address a crucial problem: PET scans are currently expensive and require the use of radioactive substances, which poses both financial and health challenges.
Geoffrey D’hondt from Heran Partners comments: “Nuclivision is uniquely positioned in the field of AI-driven image enhancement for PET scans with the Nuclarity platform. By reducing the amount of time and the amount of costly and harmful radiotracers required for accurate medical imaging, Nuclarity not only reduces the time pressure on nuclear medicine departments but also the cost and harmful environmental and health impact of PET scans.”
The startup is currently in the final phase of regulatory approval for the software platform. As soon as this is completed, the strategic entry into the European market will follow and into the American market later this year.
“The completion of the regulatory approval process marks the beginning of a new growth phase for Nuclivision that is crucial for the actual deployment and impact of their technology,” explains Sven Bakkes, Founding Partner at LUMO Labs. He continues: “We look forward to supporting the founders and the growing team of Nuclivision in this, of course with indispensable growth capital but also with expertise and frameworks in the field of business operations and impact and with opening up our network.”
Kris Vandenberk, Managing Partner at imec.istart future fund adds: “We believe that Nuclivision can set a new standard in improving PET imaging. With seamless integration into hospital systems, the platform shows strong potential. We fully support the rollout of this platform.”
This investment round follows previous investments in Nuclivision by imec.istart and Lumiares.
About Nuclivision
Nuclivision is a Belgium-based medtech company transforming nuclear medicine through AI. Founded in Ghent in 2022, the company develops intelligent software solutions that enhance nuclear imaging, making it faster, safer, and more accessible. Its medical device software, Nuclarity, reduces the need for radioactive tracers and shortens PET scan times without compromising lesion detectability—addressing key cost, safety, and environmental challenges in nuclear medicine.
Driven by a mission to improve the quality, safety, and accessibility of nuclear imaging, Nuclivision helps patients gain faster access to accurate diagnoses and appropriate treatments. By reducing radiation exposure, costs, and logistical barriers, the company also contributes to a more sustainable healthcare system through more efficient use of radiopharmaceuticals.
The founders’ team of Nuclivision is advised by professor-clinicians and seasoned entrepreneurs with deep expertise in AI and nuclear medicine. With a focus on oncology, neurology, and theranostics, the company will expand internationally across Europe and the U.S.—enabling earlier, safer detection of diseases such as cancer and Alzheimer’s.
Nuclivision media contact:
Tomas Brants, Cofounder, tomas.brants@nuclivision.com
About LUMO Labs
LUMO Rise Fund is a MEUR 100 multi-stage (Pre-Seed to Series A) impact-driven venture capital fund, with a proprietary startup coaching program for purpose-driven founders, who seek to bring technological innovations to the market to help solve social and environmental challenges.
LUMO Rise Fund invests in scalable and financially sustainable operating systems, infrastructures, and platforms based on and/or related to emerging and potentially disruptive technologies, such as Artificial Intelligence & Data, Blockchain, Internet of Things, Digital Security, and Extended Realities (AR/VR). The fund’s impact focus is best identified as the bottom-up crossroads between the following UN SDGs: Health & Wellbeing, Quality Education, Sustainable Cities & Communities, and Climate Action.
The primary investment region is Benelux and Germany, and secondary Nordics, Baltics and the Iberian Peninsula. LUMO Rise Fund is the successor fund of LUMO Fund II managed by LUMO Labs, founded in 2016 by former tech entrepreneurs Andy Lürling and Sven Bakkes.
LUMO Labs media contact:
Andy Lurling, Founding Partner; andy@lumolabs.io
For Spain: Jorge Blasco, Partner; jorge@lumolabs.io
About Heran Partners
Heran Partners is a specialist venture capital investor, committed to creating transformative impact within the life sciences and healthcare industry.
Heran Partners is based in Belgium with a clear European investment focus, founded by Annie Vereecken, Katleen Vandersmissen, Herman Verrelst and Joris Mortelmans. Driven by a dedicated team with strong scientific and entrepreneurial backgrounds, HERAN provides venture & growth capital, accompanied by a strong network, deep expertise and mentorship to start-ups and scale-ups with a solid technology platform and strong market potential.
HERAN engages at seed, Series A and Series B stage. They focus on solutions that are solving an unmet need in the market. This solution can be hardware (medtech), software (healthtech), services or a combination.
Heran Partners media contact:
Katleen Vandersmissen, Managing Partner, katleen.vandersmissen@heranpartners.com
https://www.heranpartners.com/
About imec.istart future fund
imec.istart future fund is an independent venture capital fund aimed at supporting technology companies at the (late) seed/series A stage in Belgium, The Netherlands and Italy. While our primary emphasis is on backing promising graduates of the imec.istart accelerator program, we also strategically invest in exceptional companies outside of the accelerator network. Our unwavering commitment lies in fostering long-term value-added partnerships with our portfolio companies, guiding their growth and success.
imec.istart future fund media contact:
Ruth Janssens, Managing Partner, ruth.janssens@imecistartfuturefund.com